GlassScriptPrepare for your visit
Nadeem Nimri
Cardiovascular Disease · Houston, TX · NPI 1821403775
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$3,328.23
in general payments reported to CMS, 2019-2025 · $44.32 in 2025
The $44.32 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Who reported paying
General payments only, top 6 by amount.
- Abbott Laboratories $693.30
- Zoll Services LLC (A/K/A Zoll Lifecor Corp) $420.79
- Medtronic Vascular, INC. $376.23
- Novartis Pharmaceuticals Corporation $281.24
- Boehringer Ingelheim Pharmaceuticals, INC. $268.27
- Abiomed $257.67
Drugs and devices associated with these payments
Impella Ffrct Definity Amplatzer Jardiance
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Nadeem Nimri listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/614482/nadeem-nimri